Pharmacogenomics and Cardiovascular Disease

View Sample PDF

Author(s): Emily K. Dornblaser (University of New England, USA), Craig P. Worby (University of New England, USA)and Daniel Alan Brazeau (University of New England, USA)
Copyright: 2017
Pages: 14
Source title: Emerging Applications, Perspectives, and Discoveries in Cardiovascular Research
Source Author(s)/Editor(s): Ashim Malhotra (Pacific University, USA)and Shivani Soni (California State University, Fullerton, USA & Chapman University, USA & Alabama State University, USA)
DOI: 10.4018/978-1-5225-2092-4.ch009

Keywords: Cardiovascular Medicine / Medical Diagnosis and Practice / Medical Information Science Reference / Medicine & Healthcare

Purchase

View Pharmacogenomics and Cardiovascular Disease on the publisher's website for pricing and purchasing information.

Abstract

Cardiovascular disease is one of the most prevalent disease states in the U.S. and contributes substantially to overall morbidity and mortality. The ability to effectively optimize the treatment of cardiovascular disease has a significant impact on overall disease prevention and treatment. This chapter discusses the relationship between genetic variations and their impact on medications used for the treatment of cardiovascular disorders. Key medications that are susceptible to genetic variation have been identified. The chapter describes the mechanisms by which genetic variation may contribute to altered medication concentrations or effects and briefly reviews the place in therapy for the cardiovascular medications. In addition, this chapter reviews current clinical literature to determine the overall impact these variations may have on clinical outcomes.

The IRMA Community

Research IRM

Pharmacogenomics and Cardiovascular Disease

Purchase

Abstract

Related Content

IRMA Sponsors